EGFR and lung cancer: Because RIT1 variants can confer resistance to erlotinib in PC9 cells, an EGFR-mutant lung cancer cell line8, this drug resistance phenotype could provide a powerful screening system to probe the requirements for RIT1 function in a highly controlled and robust system.